David Spencer joined Bellicum in 2012 as Chief Scientific Officer. Dr. Spencer is an inventor of CID technology, and helped develop the first clinical applications of the technology, including CaspaCIDe®, and GoCAR-T® technologies that are now advancing in human clinical trials. Prior to joining Bellicum, he served as Professor and Vice Chairman of Pathology & Immunology, Baylor College of Medicine, during which time he was a scientific advisor to the Company. Dr. Spencer oversees a robust research program focused on CID clinical applications and supports clinical development of CID-enabled products. He earned his Ph.D. at Massachusetts Institute of Technology and was a postdoctoral fellow at Stanford University.